: Recent studies focus on identifying risk factors like HSCT-TMA (Thrombotic Microangiopathy), which can exacerbate GvHD symptoms. Modern treatment strategies emphasize early detection through organ biopsies and staining for markers like C4d and C5b-9 [5, 8].

: Advanced research is exploring VHH-CAR T cells (nanobody-based chimeric antigen receptor T cells). These are designed to target specific antigens like MET in solid tumors while minimizing the "tonic signaling" that often leads to T-cell exhaustion.

Below are the most relevant current research topics and resources related to "GVH" (Graft-versus-Host) that may correspond to the context of such a file: Relevant Research & Clinical Contexts